Clinical Trial

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

Study acronym: HER2-PREDICT
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
HER2-Predict is a multi-center, observational study using biological samples from patients treated with DS-8201a in the metastatic setting. Patients will provide a baseline FFPE tumor sample and additionally, blood sample for ctDNA determination will be collected.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-02-04; most recent amendment 2025-09-02.
Status change: Recruiting → Active, Not Recruiting 2025-09-02
Trial Details
NCT Number NCT04257162
Lead Sponsor SOLTI Breast Cancer Research Group
Collaborators: Daiichi Sankyo
Conditions Metastatic Cancer
Enrollment 180 participants
Start Date 2019-12-13
Primary Completion 2025-06-30 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-09